Methods for determining the responsiveness of a Met-related cancer in a subject to treatment with a Met inhibitor. Kits for performing the disclosed methods are also provided. The present invention also provides a method of treating glioblastomamultiforme (GBM) in a subject in need thereof, the method comprises administering a therapeutically effective dose of a Met inhibitor in combination with a therapeutically effective dose of a epithelial growth factor receptor (EGFR) inhibitor.
